{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T22:20:50Z","timestamp":1770502850832,"version":"3.49.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2002,8,1]],"date-time":"2002-08-01T00:00:00Z","timestamp":1028160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2002,8]]},"DOI":"10.4065\/77.8.813","type":"journal-article","created":{"date-parts":[[2009,1,24]],"date-time":"2009-01-24T01:19:36Z","timestamp":1232759976000},"page":"813-822","source":"Crossref","is-referenced-by-count":84,"title":["Current Therapy for Multiple Myeloma"],"prefix":"10.4065","volume":"77","author":[{"given":"S. Vincent","family":"Rajkumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Kyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip R.","family":"Greipp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4065\/77.8.813_bib1","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJM199706053362307","article-title":"Multiple myeloma","volume":"336","author":"Bataille","year":"1997","journal-title":"N Engl J Med"},{"key":"10.4065\/77.8.813_bib2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3322\/canjclin.52.1.23","article-title":"Cancer statistics, 2002 [published correction appears in CA Cancer J Clin. 2002;52:119]","volume":"52","author":"Jemal","year":"2002","journal-title":"CA Cancer J Clin"},{"key":"10.4065\/77.8.813_bib3","series-title":"Myeloma: Biology and Management","first-page":"127","article-title":"The epidemiology of myeloma","author":"Herrinton","year":"1995"},{"key":"10.4065\/77.8.813_bib4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1600-0609.1993.tb00148.x","article-title":"Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I\u2014a randomized study","volume":"50","author":"Hjorth","year":"1993","journal-title":"Eur J Haematol"},{"key":"10.4065\/77.8.813_bib5","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/bjc.1996.212","article-title":"A prognostic index for multiple myeloma","volume":"73","author":"Grignani","year":"1996","journal-title":"Br J Cancer"},{"key":"10.4065\/77.8.813_bib6","series-title":"Neoplastic Diseases of the Blood","first-page":"537","article-title":"Staging, kinetics, and prognosis of multiple myeloma","author":"Greipp","year":"1996"},{"key":"10.4065\/77.8.813_bib7","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","article-title":"Smoldering multiple myeloma","volume":"302","author":"Kyle","year":"1980","journal-title":"N Engl J Med"},{"key":"10.4065\/77.8.813_bib8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"key":"10.4065\/77.8.813_bib9","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1200\/JCO.1998.16.12.3832","article-title":"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials","volume":"16","year":"1998","journal-title":"J Clin Oncol"},{"issue":"1, suppl 1","key":"10.4065\/77.8.813_bib10","first-page":"49","article-title":"Intensive treatment strategies in multiple myeloma","volume":"34","author":"Kovacsovics","year":"1997","journal-title":"Semin Hematol"},{"key":"10.4065\/77.8.813_bib11","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1056\/NEJM199402173300709","article-title":"The treatment of multiple myeloma","volume":"330","author":"Alexanian","year":"1994","journal-title":"N Engl J Med"},{"key":"10.4065\/77.8.813_bib12","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1002\/(SICI)1097-0142(19970415)79:8<1561::AID-CNCR18>3.0.CO;2-W","article-title":"Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and pred-nisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479","volume":"79","author":"Oken","year":"1997","journal-title":"Cancer"},{"key":"10.4065\/77.8.813_bib13","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1046\/j.1365-2141.2001.02857.x","article-title":"Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients","volume":"113","year":"2001","journal-title":"Br J Haematol"},{"key":"10.4065\/77.8.813_bib14","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/ajh.2830330203","article-title":"VAD-based regimens as primary treatment for multiple myeloma","volume":"33","author":"Alexanian","year":"1990","journal-title":"Am J Hematol"},{"key":"10.4065\/77.8.813_bib15","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood.V80.4.887.887","article-title":"Primary dexamethasone treatment of multiple myeloma","volume":"80","author":"Alexanian","year":"1992","journal-title":"Blood"},{"issue":"1, suppl 1","key":"10.4065\/77.8.813_bib16","first-page":"61","article-title":"The role of autologous hematopoietic stem cell transplantation in multiple myeloma","volume":"34","author":"Harousseau","year":"1997","journal-title":"Semin Hematol"},{"issue":"1, suppl 1","key":"10.4065\/77.8.813_bib17","first-page":"67","article-title":"Biology and therapy of multiple myeloma in 1996","volume":"34","author":"Barlogie","year":"1997","journal-title":"Semin Hematol"},{"key":"10.4065\/77.8.813_bib18","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/00000441-199503000-00006","article-title":"Refractory and relapsing multiple myeloma treated by blood stem cell transplantation","volume":"309","author":"Gertz","year":"1995","journal-title":"Am J Med Sci"},{"key":"10.4065\/77.8.813_bib19","first-page":"815a","volume":"98","author":"Blade","year":"2001","journal-title":"Blood"},{"key":"10.4065\/77.8.813_bib20","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood.V93.1.51","article-title":"Age is not a prognostic variable with autotransplants for multiple myeloma","volume":"93","author":"Siegel","year":"1999","journal-title":"Blood"},{"key":"10.4065\/77.8.813_bib21","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1182\/blood.V99.3.731","volume":"99","author":"Moreau","year":"2002","journal-title":"Blood"},{"key":"10.4065\/77.8.813_bib22","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1200\/JCO.2001.19.17.3771","article-title":"Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial","volume":"19","author":"Stewart","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.4065\/77.8.813_bib23","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/sj.bmt.1701805","article-title":"Autologous stem cell transplantation for relapsed and primary refractory myeloma","volume":"23","author":"Rajkumar","year":"1999","journal-title":"Bone Marrow Transplant"},{"issue":"11, pt 1","key":"10.4065\/77.8.813_bib24","first-page":"816a","article-title":"Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma [abstract]","volume":"98","author":"Singhal","year":"2001","journal-title":"Blood"},{"issue":"11, pt 1","key":"10.4065\/77.8.813_bib25","first-page":"683a","article-title":"Autologous stem cell transplantation (ASCT) after nonmyelosuppressive induction therapy with dexamethasone alone is safe and effective for newly diagnosed multiple myeloma (MM) pts who receive high dose chemotherapy (HDC) [abstract]","volume":"98","author":"Anagnostopoulos","year":"2001","journal-title":"Blood"},{"issue":"11, pt 1","key":"10.4065\/77.8.813_bib26","first-page":"849a","article-title":"Combination therapy with thalidomide plus dexamethasone (Thal\/Dex) for newly diagnosed myeloma (MM) [abstract]","volume":"98","author":"Rajkumar","year":"2001","journal-title":"Blood"},{"key":"10.4065\/77.8.813_bib27","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1046\/j.1365-2141.1997.2783095.x","article-title":"Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma","volume":"98","author":"Goldschmidt","year":"1997","journal-title":"Br J Haematol"},{"key":"10.4065\/77.8.813_bib28","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s002770050398","article-title":"Successful mobilization of peripheral blood stem cells in heavily pretreated myeloma patients with G-CSF alone","volume":"76","author":"Kroger","year":"1998","journal-title":"Ann Hematol"},{"key":"10.4065\/77.8.813_bib29","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131","article-title":"High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? results of a multicenter sequential randomized clinical trial","volume":"92","author":"Fermand","year":"1998","journal-title":"Blood"},{"issue":"suppl 1, pt 1","key":"10.4065\/77.8.813_bib30","first-page":"685a","article-title":"Front-line or rescue autologous bone marrow transplantation (ABMT) following a first course of high dose melphalan (HDM) in multiple myeloma (MM): preliminary results of a prospective randomized trial (CIAM protocol) [abstract]","volume":"88","author":"Facon","year":"1996","journal-title":"Blood"},{"key":"10.4065\/77.8.813_bib31","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V89.3.789","article-title":"Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma","volume":"89","author":"Barlogie","year":"1997","journal-title":"Blood"},{"key":"10.4065\/77.8.813_bib32","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1182\/blood.V84.3.950.950","article-title":"High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants","volume":"84","author":"Vesole","year":"1994","journal-title":"Blood"},{"key":"10.4065\/77.8.813_bib33","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3109\/10428199609051725","article-title":"Hematopoietic stem cell transplants for multiple myeloma","volume":"22","author":"Tricot","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"10.4065\/77.8.813_bib34","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1182\/blood.V95.12.4008","article-title":"Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities","volume":"95","author":"Desikan","year":"2000","journal-title":"Blood"},{"key":"10.4065\/77.8.813_bib35","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood.V93.1.55","article-title":"Total therapy with tandem transplants for newly diagnosed multiple myeloma","volume":"93","author":"Barlogie","year":"1999","journal-title":"Blood"},{"key":"10.4065\/77.8.813_bib36","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/asheducation-2001.1.157","article-title":"Multiple myeloma","author":"Dalton","year":"2001","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"11, pt 1","key":"10.4065\/77.8.813_bib37","first-page":"402a","article-title":"High-dose melphalan and second autografts for myeloma relapsing after one autograft: results equivalent to tandem autotransplantation [abstract]","volume":"98","author":"Sirohi","year":"2001","journal-title":"Blood"},{"issue":"suppl 2","key":"10.4065\/77.8.813_bib38","first-page":"126","article-title":"Allogeneic bone marrow transplantation for the treatment of multiple myeloma: an overview of published reports","volume":"13","author":"Cavo","year":"1995","journal-title":"Stem Cells"},{"key":"10.4065\/77.8.813_bib39","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0889-8588(18)30354-X","article-title":"Allogeneic bone marrow transplantation in multiple myeloma","volume":"6","author":"Tura","year":"1992","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.4065\/77.8.813_bib40","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1182\/blood.V90.10.4206","article-title":"Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation","volume":"90","author":"Lokhorst","year":"1997","journal-title":"Blood"},{"key":"10.4065\/77.8.813_bib41","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1182\/blood.V88.7.2787.bloodjournal8872787","article-title":"Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome","volume":"88","author":"Bensinger","year":"1996","journal-title":"Blood"},{"key":"10.4065\/77.8.813_bib42","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sj.bmt.1701280","article-title":"High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma","volume":"22","author":"Cavo","year":"1998","journal-title":"Bone Marrow Transplant"},{"issue":"pt 1","key":"10.4065\/77.8.813_bib43","first-page":"480a","article-title":"Non-myeloablative peripheral blood stem cell (PBSC) allografts following cytoreductive autotransplants for treatment of multiple myeloma (MM) [abstract]","volume":"96","author":"Molina","year":"2000","journal-title":"Blood"},{"issue":"11, pt 1","key":"10.4065\/77.8.813_bib44","first-page":"435a","article-title":"Combining an allogeneic graft-vs-myeloma effect with high-dose autologous stem cell rescue in the treatment of multiple myeloma [abstract]","volume":"98","author":"Maloney","year":"2001","journal-title":"Blood"},{"key":"10.4065\/77.8.813_bib45","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1200\/JCO.20.5.1295","article-title":"Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning","volume":"20","author":"Badros","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.4065\/77.8.813_bib46","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1177\/107327489800500303","article-title":"Interferon in the treatment of multiple myeloma","volume":"5","author":"Shustik","year":"1998","journal-title":"Cancer Control"},{"key":"10.4065\/77.8.813_bib47","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJM199005173222005","article-title":"Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy","volume":"322","author":"Mandelli","year":"1990","journal-title":"N Engl J Med"},{"key":"10.4065\/77.8.813_bib48","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1200\/JCO.1995.13.9.2354","article-title":"Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group","volume":"13","author":"Browman","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.4065\/77.8.813_bib49","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.1995.tb08364.x","article-title":"Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study","volume":"89","author":"Westin","year":"1995","journal-title":"Br J Haematol"},{"key":"10.4065\/77.8.813_bib50","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.1994.12.11.2405","article-title":"Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study","volume":"12","author":"Salmon","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.4065\/77.8.813_bib51","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/0959-8049(94)00452-B","article-title":"A comparison of poly-chemotherapy and melphalan\/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma: a prospective trial of the German Myeloma Treatment Group","volume":"31A","author":"Peest","year":"1995","journal-title":"Eur J Cancer"},{"key":"10.4065\/77.8.813_bib52","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/oxfordjournals.annonc.a059217","article-title":"Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies","volume":"6","author":"Ludwig","year":"1995","journal-title":"Ann Oncol"},{"key":"10.4065\/77.8.813_bib53","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.1998.16.3.890","article-title":"Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study","volume":"16","author":"Salmon","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.4065\/77.8.813_bib54","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/blood.V99.9.3163","article-title":"Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients","volume":"99","author":"Berenson","year":"2002","journal-title":"Blood"},{"key":"10.4065\/77.8.813_bib55","doi-asserted-by":"crossref","first-page":"734","DOI":"10.7326\/0003-4819-132-9-200005020-00009","article-title":"The role of bisphosphonates in multiple myeloma","volume":"132","author":"Kyle","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.4065\/77.8.813_bib56","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma","volume":"334","author":"Berenson","year":"1996","journal-title":"N Engl J Med"},{"key":"10.4065\/77.8.813_bib57","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","article-title":"Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events","volume":"16","author":"Berenson","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.4065\/77.8.813_bib58","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"key":"10.4065\/77.8.813_bib59","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","article-title":"Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases [published correction appears in Cancer. 2001;91:1956]","volume":"91","author":"Berenson","year":"2001","journal-title":"Cancer"},{"key":"10.4065\/77.8.813_bib60","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000203625","article-title":"Recombinant human erythropoietin in the treatment of multiple myeloma-associated anemia","volume":"98","author":"Mittelman","year":"1997","journal-title":"Acta Haematol"},{"key":"10.4065\/77.8.813_bib61","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1600-0609.1997.tb01677.x","article-title":"Clinical results of recombinant erythropoietin in transfusion-dependent patients with refractory multiple myeloma: role of cytokines and monitoring of erythropoiesis","volume":"58","author":"Musto","year":"1997","journal-title":"Eur J Haematol"},{"key":"10.4065\/77.8.813_bib62","series-title":"Myeloma","first-page":"223","article-title":"Infections: principles of prevention and therapy","author":"Kelleher","year":"2002"},{"key":"10.4065\/77.8.813_bib63","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0140-6736(94)90180-5","article-title":"Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma","volume":"343","author":"Chapel","year":"1994","journal-title":"Lancet"},{"key":"10.4065\/77.8.813_bib64","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/BF02113579","article-title":"Pneumocystis carinii pneumonia in HIV-negative patients with haematologic disease","volume":"25","author":"van der Lelie","year":"1997","journal-title":"Infection"},{"key":"10.4065\/77.8.813_bib65","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1001\/archinte.1994.00420170079008","article-title":"Treatment of cancer-associated hypercalcemia: double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone","volume":"154","author":"Gucalp","year":"1994","journal-title":"Arch Intern Med"},{"key":"10.4065\/77.8.813_bib66","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials","volume":"19","author":"Major","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.4065\/77.8.813_bib67","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1001\/archinte.150.8.1693","article-title":"Renal failure in multiple myeloma: pathogenesis and prognostic implications","volume":"150","author":"Alexanian","year":"1990","journal-title":"Arch Intern Med"},{"key":"10.4065\/77.8.813_bib68","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/archinte.1990.00390160111022","article-title":"Treatment of renal failure associated with multiple myeloma: plasmapheresis, hemodialysis, and chemotherapy","volume":"150","author":"Johnson","year":"1990","journal-title":"Arch Intern Med"},{"key":"10.4065\/77.8.813_bib69","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/(SICI)1096-8652(199806)58:2<142::AID-AJH10>3.0.CO;2-D","article-title":"Acute renal failure precipitated by non-steroidal anti-inflammatory drugs (NSAIDs) in multiple myeloma","volume":"58","author":"Yussim","year":"1998","journal-title":"Am J Hematol"},{"key":"10.4065\/77.8.813_bib70","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1056\/NEJM198707163170315","article-title":"Multiple myeloma in naproxen-induced acute renal failure [letter]","volume":"317","author":"Wu","year":"1987","journal-title":"N Engl J Med"},{"key":"10.4065\/77.8.813_bib71","series-title":"Myeloma","first-page":"367","article-title":"The role of radiotherapy","author":"Shrieve","year":"2002"},{"key":"10.4065\/77.8.813_bib72","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1200\/JCO.1999.17.7.2173","article-title":"High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial","volume":"17","author":"Vesole","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.4065\/77.8.813_bib73","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis","volume":"91","author":"D'Amato","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.4065\/77.8.813_bib74","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma [published correction appears in N Engl J Med. 2000;342:364]","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"10.4065\/77.8.813_bib75","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.V98.2.492","article-title":"Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients","volume":"98","author":"Barlogie","year":"2001","journal-title":"Blood"},{"key":"10.4065\/77.8.813_bib76","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1053\/ctrv.2000.0188","article-title":"A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma","volume":"26","author":"Rajkumar","year":"2000","journal-title":"Cancer Treat Rev"},{"key":"10.4065\/77.8.813_bib77","doi-asserted-by":"crossref","first-page":"897","DOI":"10.4065\/75.9.897","article-title":"Thalidomide in the treatment of relapsed multiple myeloma","volume":"75","author":"Rajkumar","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"10.4065\/77.8.813_bib78","first-page":"867","article-title":"Current status of thalidomide in the treatment of cancer","volume":"15","author":"Rajkumar","year":"2001","journal-title":"Oncology (Huntingt)"},{"key":"10.4065\/77.8.813_bib79","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1200\/JCO.2001.19.16.3593","article-title":"Thalidomide in the treatment of plasma cell malignancies [editorial]","volume":"19","author":"Rajkumar","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.4065\/77.8.813_bib80","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJM199512283332608","article-title":"Seminars in Medicine of the Beth Israel Hospital, Boston: clinical applications of research on angiogenesis","volume":"333","author":"Folkman","year":"1995","journal-title":"N Engl J Med"},{"key":"10.4065\/77.8.813_bib81","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/ajh.2830500103","article-title":"Bone marrow of patients with active multiple myeloma: angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44","volume":"50","author":"Vacca","year":"1995","journal-title":"Am J Hematol"},{"key":"10.4065\/77.8.813_bib82","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/sj.leu.2401336","article-title":"Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma","volume":"13","author":"Rajkumar","year":"1999","journal-title":"Leukemia"},{"key":"10.4065\/77.8.813_bib83","first-page":"3111","article-title":"Prognostic value of bone marrow angiogenesis in multiple myeloma","volume":"6","author":"Rajkumar","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.4065\/77.8.813_bib84","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0149-2918(00)88289-2","article-title":"S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide","volume":"21","author":"Zeldis","year":"1999","journal-title":"Clin Ther"},{"key":"10.4065\/77.8.813_bib85","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1056\/NEJM200106213442516","article-title":"Deep venous thrombosis and thalidomide therapy for multiple myeloma [letter]","volume":"344","author":"Osman","year":"2001","journal-title":"N Engl J Med"},{"key":"10.4065\/77.8.813_bib86","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1182\/blood.V98.5.1614","article-title":"Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy","volume":"98","author":"Zangari","year":"2001","journal-title":"Blood"},{"issue":"11, pt 1","key":"10.4065\/77.8.813_bib87","first-page":"775a","article-title":"A phase 1 study of oral CC5013, an immunomodulatory thalidomide (Thal) derivative, in patients with relapsed and refractory multiple myeloma (MM) [abstract]","volume":"98","author":"Richardson","year":"2001","journal-title":"Blood"},{"issue":"11, pt 1","key":"10.4065\/77.8.813_bib88","first-page":"775a","article-title":"Results of phase I study of CC-5013 for the treatment of multiple myeloma (MM) patients who relapse after high dose chemotherapy (HDCT) [abstract]","volume":"98","author":"Zangari","year":"2001","journal-title":"Blood"},{"issue":"11, pt 1","key":"10.4065\/77.8.813_bib89","first-page":"774a","article-title":"Phase II study of PS-341, a novel proteasome inhibitor, alone or in combination with dexamethasone in patients with multiple myeloma who have relapsed following front-line therapy and are refractory to their most recent therapy [abstract]","volume":"98","author":"Richardson","year":"2001","journal-title":"Blood"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611620247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611620247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T01:14:18Z","timestamp":1589505258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611620247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,8]]},"references-count":89,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2002,8]]}},"alternative-id":["S0025619611620247"],"URL":"https:\/\/doi.org\/10.4065\/77.8.813","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2002,8]]}}}